Key result
Older patients (>40 years) with essential hypertension had significantly lower urinary kallikrein excretion compared to age-matched normotensive controls (67.2 vs 105.1 micrograms/24h).
Why the study?
Does urinary kallikrein excretion differ between patients with essential hypertension and normotensive controls, and how does it relate to age and the renin-angiotensin-aldosterone system?
Case-Control (n=65)
Does urinary kallikrein excretion differ between patients with essential hypertension and normotensive controls, and how does it relate to age and the renin-angiotensin-aldosterone system?
Lower urinary kallikrein excretion in older hypertensive patients appears secondary to long-standing high blood pressure rather than being influenced by the renin-angiotensin-aldosterone system.
No immediate clinical implications; hypothesis-generating for urinary kallikrein as marker of chronic hypertension effects in older patients.
The relevance of age and activity of the renin-angiotensin-aldosterone system to the excretion of urinary kallikrein (Ukal) was studied in twenty-five patients with essential hypertension and forty normotensive controls. The age range for both study groups was 20-60 years. Ukal was measured by radioimmunoassay and by an amidolytic assay. Results of both assays correlated closely (r = 0.93, n = 65, P less than 0.001). For all hypertensives Ukal excretion was not significantly different from that of controls. However, older hypertensives (greater than 40 years, n = 13) had a significantly lower Ukal excretion than normotensives of the same age (n = 20) (radioimmunoassay 67.2 (SEM 7.2) v. 105.1 (SEM 8.4) micrograms (24 h)-1; and amidolytic method 0.84 (SEM 0.10) v. 1.13 (SEM 0.08) U (24 h)-1). No correlation was found between Ukal excretion and plasma renin or aldosterone. In fact, the aldosterone level was highest in older hypertensives. In conclusion, the lower Ukal excretion in hypertensives over 40 is likely to be secondary to the long-standing high blood pressure. Under basal conditions, Ukal excretion seems little influenced by the activity of the renin-angiotensin-aldosterone system.
No takes yet. Share an insight, caveat, or question.
Koolen et al. (1984) conducted a case-control in Essential hypertension (n=65). Essential hypertension vs. Normotensive controls was evaluated on Urinary kallikrein (Ukal) excretion in participants >40 years (micrograms/24h). Older patients (>40 years) with essential hypertension had significantly lower urinary kallikrein excretion compared to age-matched normotensive controls (67.2 vs 105.1 micrograms/24h).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: